Neoadjuvant Camrelizumab (an Anti-Pd-1 Antibody) Plus Chemotherapy or Apatinib (a VEGFR-2 Inhibitor) for Initially Unresectable Stage II–III Non-Small-cell Lung Cancer: a Multicentre, Two-Arm, Phase 2 Exploratory Study